A detailed history of Park West Asset Management LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Park West Asset Management LLC holds 1,862,988 shares of TBPH stock, worth $17.9 Million. This represents 1.21% of its overall portfolio holdings.

Number of Shares
1,862,988
Previous 1,700,000 9.59%
Holding current value
$17.9 Million
Previous $14.4 Million 4.16%
% of portfolio
1.21%
Previous 1.14%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.66 - $10.25 $1.25 Million - $1.67 Million
162,988 Added 9.59%
1,862,988 $15 Million
Q2 2024

Aug 14, 2024

BUY
$8.29 - $9.92 $4.5 Million - $5.38 Million
542,837 Added 46.91%
1,700,000 $14.4 Million
Q1 2024

May 15, 2024

BUY
$8.22 - $11.59 $2.11 Million - $2.98 Million
257,163 Added 28.57%
1,157,163 $10.4 Million
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $9.29 Million - $12.3 Million
-1,083,251 Reduced 54.62%
900,000 $10.1 Million
Q3 2023

Nov 14, 2023

BUY
$8.38 - $10.44 $2.2 Million - $2.74 Million
262,500 Added 15.25%
1,983,251 $17.1 Million
Q2 2023

Aug 14, 2023

SELL
$10.16 - $11.92 $1.82 Million - $2.14 Million
-179,452 Reduced 9.44%
1,720,751 $17.8 Million
Q1 2023

May 15, 2023

SELL
$9.87 - $11.44 $198,594 - $230,184
-20,121 Reduced 1.05%
1,900,203 $20.6 Million
Q4 2022

Feb 14, 2023

BUY
$9.65 - $11.34 $9,360 - $10,999
970 Added 0.05%
1,920,324 $21.5 Million
Q3 2022

Nov 14, 2022

SELL
$8.39 - $10.22 $10.5 Million - $12.8 Million
-1,253,900 Reduced 39.51%
1,919,354 $19.5 Million
Q2 2022

Aug 15, 2022

BUY
$8.41 - $10.34 $23.8 Million - $29.3 Million
2,833,254 Added 833.31%
3,173,254 $28.8 Million
Q1 2022

May 16, 2022

BUY
$8.33 - $12.96 $2.83 Million - $4.41 Million
340,000 New
340,000 $3.25 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $640M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Park West Asset Management LLC Portfolio

Follow Park West Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park West Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Park West Asset Management LLC with notifications on news.